CAPR - Earnings call transcript Q1 2019 | Capricor Therapeutics, Inc.

Due to licensing restrictions, you must log in to view earnings call transcripts.

Operator

Welcome to Capricor Therapeutics First Quarter 2019 Conference Call. My name is Chris and I'll be your operator for today's call. [Operator Instructions] As a reminder this call will be recorded. I would now like to turn the call over to Capricor CFO, AJ Bergmann. Please go ahead.

AJ Bergmann

afternoon. good and you Thank

uses future the development our risks regarding may including report from results existing a candidates, information, periodic annual developments timing our Before we will product candidates forward-looking our quarterly plans that presentation. are and and to filings, state we cause change and our other like plans statements of statements subject additional intended the anticipated our in other I potential on involving making SEC. are and present certain possible would our things materially forward-looking among resources. be regarding today's our include current reports. are and to described that safety based product These of preclinical forward-looking in contained These plans the and involve may utilization our differ of investment and statements. with to to number those including that statements conduct and start, efficacy, statements expectations These filings regulatory regulatory and and of clinical assumptions research cash and made studies, risks our data, a during actual uncertainties

call on to not to update the place I Linda forward-looking You're to cautioned we Marbán, undue these over any that, and turn will obligation reliance CEO. disclaim statements such With statements.

Linda Marbán

first for afternoon, update Good for our conference quarter call. you us joining and and thank

an continuing platform analysis from We the DMD of on provide the we we Although the the while analysis prepare to you clinical and this update pleased to our technology. exosome been on trial. gather eagerly for both with today. quarter of had a busy call be background development continue along one community as programs first HOPE-X, await will brief, the the the in the interim I'm with interim HOPE-X data are data

of interim our our the statisticians, analysis the like clinical steering of teams data would working committee rest we analysis. plan types and HOPE-X actively are with We to the for

our in in have that mentioned more forward of from will best the and believe adjudication path of I last design who of dose than trial patients safe approximately us one terms call help we had quarter, inform for data As HOPE-X. the XX

but on be are be the going track results quarter of the the of the we to on targeted share impact third the of dystrophy. the to X.X other limb at analysis many primary looking muscular of and early the We at and during into to able upper endpoint of exploratory secondary carefully both Duchenne detail, pathogenesis of of efficacy too of the also course Without will performance endpoints the XXXX. CAP-XXXX X.X measure the much interim evaluate part

our continuing path conservation you as plan the the will the data will us capital necessary course us best data, on is the management. further decide treatment to Of and clinical performing before to the to we DMD. well for potential based the promising, in Capricor provide this attempt of DMD of To CAP-XXXX interim believe remind enable efficacy determine the as resource and analysis appears flexibility their CAP-XXXX enroll raise if forward an trial. to to trial, complete and

suggest or pursue not forward, does likely strategic programs data allocate other will the if resources other However, to the path we options.

I for therapeutic and like while may next current development potentially a saying fruition. exosome update program. been it coming appears that to cellular on of also have Now you wave become that biotechnology, these information of packets for I to now the this would our is

months exosomes there San approaching U.S. there cell as terms The molecule. some active therapy is them trauma or made cells, directly using Antonio, CAP-XXXX. vivo quite benefit making exosome of or That Institute program effective showing discovering Linking realizing cargo may utility. exosome from in the is they in the efforts Army endogenous are just A ingredient the now small also whether and by are the We RNA of the in we deliver a ability injuries. a cross as potential and data very the be why vitro study to CDC vehicle United cell on States interesting military announced use exosome continues focusing to of trauma collaboration using our we suggests related Texas likely vast that for which to cells. potentially API of others to then by the have of the come a all exosome. is an as is Research now located in payloads progress the injuries. that harnessing the their observation could long related with become are be few to choice This exosomes player membrane, in the a ago not opportunities the attenuating we to the biological power become to the story way Due that see important of gene, that Surgical pharmaceutical for the exosome to to well delivery

be in could freezing As of future. on use allows that technology Capricor ideal other for relevant it the for words has preparing require are that do an ready battlefield candidate exosomes the field not

Our are are exosomes we as types of by and burns, Institute radiation, we the other investigate the U.S. pain to our we hoping data intrigued this collaboration in treating injury. as as utility of colleagues traumatic and Army expand of are

cell if and biotechnology Recently we the reflection the delivery is mechanistically We on exosome plans for our Biosciences vehicles. work exosomes. military announced future Kodiak over early change a that movement entire enter this continue We a is the together. is Those energy that fund its community around field positive a end exosomes the We've explore to branch the an to way. we carefully been years fund think from have believe therapeutics. IPO and exosomes towards the had use discussion behavior power Kodiak few and the with of the potentially in BARDA exosome. as past the have watching this investment see we believe can to of Through moving of we which that controlled engineered that

producing, exosomes. Our experience work in and capitalizes on testing characterizing our

using are to We at the or the carry RNAs inflammation. looking exosomes targeting proteins payloads with specific

treat for addressing development and While exosome of classic has of diseases of as thinking, candidate working variety remained our towards pipeline CAP-XXXX exosome are product our as avenues explained highlight inflammation diseases. as a developing fibrosis. the we DMD program I also clinical forefront of want to at biologic, to of multiple the in we a our next have

providing at eagerly also we any they data So focusing are the our and look become will HOPE-Xinterim in exosome for AJ the you financials summary, for review from forward as waiting Mr. to Again, our you, CFO, analysis Bergmann, we I'll on time. available. AJ? time. now your turn thank our update who you while program to Thank call this over this back

AJ Bergmann

This provided Thank basis. financials a of quarter press you, summary XXXX first our on release Linda. afternoon's a GAAP

also our become well soon may the on be to available as form accessible website company to which we expect section the XX-Q, You as report will of on and financial SEC refer website. quarterly our

stock-based compensation, and approximately XXXX. securities program. on cash QX million QX approximately Capricor equivalents company's $X.X expects and million compared and As Based million and in securities and excluding $X.X its and XXXX.We the administrative back to our cash its was QX turn programs questions. approximately marketable cash, compared of expense $X.X With line projections, was XX, direct plans compensation, and of open expense DMD March call Linda focus marketable quarter $XXX,XXX cash, approximately on the our our totaled was XXXX and over QX operations manage that XXXX. our XXXX. approximately that, XXXX XXXX, for development cash to continued equivalents general activities $X.X XXXX, fund December million excluding I'll approximately the and million In expenses then operating into to up first will in million, the $X.X current our fourth other development Again stock-based XX, net our in to in research and our exosome the research approximately quarter in compared on of used $X.X to

Linda Marbán

Thank to and we there update Capricor this look we as at AJ. to also through call progress you. you, forward you move seeing continue out meetings joining Thank and XXXX. Thank to all for of you you on the

Operator

[Operator Instructions] first question line H.C. Joe our with Pantginis And comes of Wainwright. from the

Your line is now open.

Joe Pantginis

just some perspective Linda, said prepared to wondering around I comments too go can but you're in detail yet, the much was I if not interim start up know outcomes. set you you into maybe your

some of to confidence and perspective obviously back on endpoints the you would the said the think X.X, to X.X Thanks. I out these guess enroll RMAT so to and give maybe be endpoint more you poll your status. outcomes of a you go endpoint even You're would patients lot FDA like a that leverage focus on primary looking primary

Linda Marbán

So and are your well appropriate. timed comments

anticipate what to been me the at let to do able to So the that movement don't to product? with reemphasize what what being doing, data direction. we've the to register FDA, should we to we is from we think want need like those we the have to looking show So we interim, we'd see but register in have that

to upper that see the X.X that both compare does performance forward. like X.X of at It data the measures patients in the feel and modulation. actually you mean? in we've upper how a that are at fact potential preparing endpoint they got lost the We means HOPE-X, we with of gather recall all have the function limb that that potentially about performance want talked the of version data as losing registration X would from on the primary measurement FDA upper those what that X.X. we the be looking valuable will and So to their the path the efficacy look I've of limb very limb be for To

going at them correlation relationship the our is function this is the we're different meeting outcomes, looking as all between collaboration December of potential to to FDA cardiac of part there of be looking in looking and parameters, us what other respiratory XXXX. do in measures at RMAT because again Additionally with improvement skeletal, HOPE of of for a and asked whether

another now. some skeletal [indiscernible] of we're that it'd plants are the we've analysis really or and story or and muscle, and function building improvement built whether build systemic be the on of cardiac based in respiratory way that life We're of again, seeing in. some will structure those So questionnaires muscle, quality things

Operator

question next comes of McCarthy our And from with Jason Maxim Group. line the

open. Your is now line

Jason McCarthy

you a Kodiak on news focus and been watching new exosome space adding touched on you like coming the actually, this even the a now guys and exosome before, Brainstorm program. IPO access with the As this to we've bit companies

a bit next steps could color when us start give you we can do more on see So program and data? think some you to for that the stage early

Linda Marbán

membrane of with a the is really But cross we bioactivity following sort mechanism call part exosomes cell mode what and fun the find have what excited this along intracellular about many sort out there's So the to of are that companies coming been by the that while of same have also for are cells. barrier to the intercellular action They now of able communication, and payloads are journey and about can everything my preferred talked And started venues, the as exosomes prepared so trajectory. that that others in exosomes. five biologic I were produced is communication general by blood access have of cells many also we the discovering to that we it. to from deliver they the cells other comments exosomes and were actually by mentioned can the in vein off and cost the define we'll we

are sharing there's And then are taking outside we that custom our with the targeting so be you could tropism by RNA delivered properties and it exosome collected drive becomes also ability data, inside the and with own contents the the We adding molecule be clear or past exploring to or making so as tropic now something we words to something approaching have of forwards have we mind, some in to small intracellular. will we public the ways even as gets RNA and decisions exosomes so have or more data design that of arena. that the on do micro natural definitely deriving our in advantage other in and a

Jason McCarthy

collaborations non-dilutive payload it this custom a And Would actually to on using possibly as drug touch then that way a them leverage could up bit the and funding more open exosomes possibly as to platform way partnerships a could be sources? the look delivery. for and at

Linda Marbán

bio Yes, big of to indicates at is scenarios starts I that so, pay we've what are from attention, of different to the for that we've been talking to really a meetings while is number exosomes some to they biotech everything many JPMorgan say and had and to colloquial pharma, partners ARP that and note can pay big attention starting in settings. meetings,

we've We a in so are space, and also a out of we're that I are ability leaders this head, this known for therapeutics. senior been the with their the of to as but potential our going the definitely while, our forward engaging and on actively development opportunity. be have to so divulging some definitely we people it razor-sharp who biology for the getting the opinion feedback will have that talking excited the point move there talking made program in that in about we of some those at say, been key top people can not space our we to basic are discoveries

Operator

And today's Linda Instructions] for session. further Marbán, I would CEO back remarks. any conclude [Operator call like turn does the to question-and-answer that to now

Linda Marbán

call you an nice providing the we quarter. Thank were update in for the forward today. questions for asked next listening to to you a and Thank that Have day. look the

Operator

Ladies today's conclude in and for does program. conference. you today's gentlemen, thank This participating

everyone great day. may all and a disconnect have You

Capricor Therapeutics (CAPR) 13 May 192019 Q1 Earnings call transcript